Nausicaa Ventures et al. invest €7.7m in Bone Therapeutics

Existing investors include Nausicaa Ventures, BAMS Angels Fund I and Life Science Research Partners. Societe Regionale d'Investissement de Wallonie (SRIW) and Sambrinvest, both of which are supported by Belgium's Walloon region, are new investors in the company.

The series-D round will support the company in developing its lead product Preob.

Company
Bone Therapeutics is a Gosselies-based pharmaceuticals company, specialised in cell therapy products for the treatment of bone diseases. Its lead product, trademarked Preob, is an autologous bone cell therapy product for the treatment of osteonecrosis and non-union fractures. Preob is currently in phase III clinical trials. The company was founded in 2006.

People
Chris Buyse led the investment on behalf of Life Science Research Partners. Enrico Bastianelli is CEO of Bone Therapeutics. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Early-stage
• Benelux
• Belgium